Ipsen (FR:IPN) has released an update.
Ipsen has revealed promising new data from the Phase III ELATIVE trial, showing that its experimental drug elafibranor significantly slows disease progression and improves itch-related quality of life in patients with primary biliary cholangitis (PBC). After 78 weeks, 70% of patients treated with elafibranor met the composite endpoint of disease progression slowdown, contrasting sharply with 0% in the placebo group. These results, presented at the EASL congress, demonstrate elafibranor’s potential as a first-in-class PPAR agonist treatment option for PBC, a rare autoimmune liver disease.
For further insights into FR:IPN stock, check out TipRanks’ Stock Analysis page.
